Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of TRS005 in relapsed or refractory CD20-positive diffuse large B-cell lymphoma
CTR20252927Phase 2Active
- Sponsor
- Teruisi Biopharma
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TRS005 in diffuse large B-cell lymphoma (DLBCL), sponsored by Teruisi Biopharma. Started Oct 2025; status: active.
02
Drugs
TRS005
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20252927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252927.